Navigation Links
Vantia Therapeutics' Pipeline Continues to Mature
Date:3/24/2009

argeted therapy.

There has also been progress in Vantia Therapeutics' preclinical portfolio. The lead indications for the kallikrein inhibitor candidate VA118020, which moved into preclinical development at the end of last year, will be asthma and COPD. Clinical trials are expected to start in 2010. The company has also initiated a new programme involving an oral plasma kallikrein inhibitor which may have potential in the treatment of hereditary angioedema (HAE). HAE, which is thought to affect up to 15,000 people world wide, is characterised by episodes of swelling in various parts of the body including the airways. It can lead to pain, nausea, vomiting and death by asphyxiation, and an oral treatment would be expected to provide advantages over existing therapies.

Dr Jim Phillips, CEO of Vantia Therapeutics, said, 'Vantia is pleased to report that its two lead drug candidates continue to make clinical progress, and is looking forward to the trial results. As the next development steps proceed we will be engaging with potential partners for these products. In addition, our preclinical progress emphasises the ability of Vantia's small molecule library to populate our pipeline and our expertise in this area.'

Notes to Editors

About Vantia Therapeutics:

Vantia Therapeutics is a UK-based R&D company focused on first-in-class therapies for recognised markets which are underserved by current therapies. Formed in 2008 as a spin-out of Ferring Research Ltd's small molecule R&D, it has two clinical phase products, VA106483 for the treatment of nocturia in BPH patients and VA111913 for the treatment of dysmenorrhoea, as well as preclinical and discovery programmes based on protease inhibition with potential in the areas of oncology and inflammation. The company's investors include MVM Life Science Partners, SV Life Sciences and Novo A/S. Vantia Therapeutics is situated on Sou
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014  Sage Analytics ( www.sageanalytics.com ... equipment for the testing of marijuana potency and ... new Luminary™ Profiler, the industry,s first product suite ... a cost-effective, portable unit. Designed from ... of the cannabis industry, the Luminary™ Profiler utilizes ...
(Date:12/19/2014)... 18, 2014 Capnia, Inc. (NASDAQ: ... medical diagnostics based on its proprietary Sensalyze™ Technology ... announced financial results for the third quarter and ... "Following the completion of our initial public offering ... the recently initiated CoSense® commercial launch," said Anish ...
(Date:12/19/2014)... Ky. , Dec. 18, 2014 Baptist Health ... States to receive full Atrial Fibrillation with Electrophysiology ... Care (SCPC). Atrial fibrillation is the most common ... that in some cases can lead to stroke and possible ... United States have atrial fibrillation and the numbers ...
Breaking Medicine Technology:Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3
... Inc. (NASDAQ: QCOR ) today announced that ... Tuesday, April 26, 2011 after the close of the ... call and webcast on Tuesday, April 26, 2011 at ... results and highlights of the first quarter, as well ...
... April 18, 2011 Amarin Corporation plc (Nasdaq: ... cardiovascular disease, today reported positive, statistically significant top-line results from ... The Phase 3 trial met its primary and secondary efficacy ... doses. The purpose of the ANCHOR trial ...
Cached Medicine Technology:Questcor to Report First Quarter 2011 Earnings and Conduct Conference Call on April 26, 2011 2Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 2Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 3Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 4Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 5Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 6Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 7Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 8
(Date:12/22/2014)... Only weeks following the announcement that Henderson, Nevada ... a battery manufacturer create 29 well-paying jobs in Mojave ... launching in Henderson to deliver yet another win ... sector is going to build a stronger middle class ... works with small businesses that rely on middle class ...
(Date:12/22/2014)... December 22, 2014 In recognition of ... sales to Hero Reward, a local organization that provides ... , Located on a couple hundred acres ... Program offers lodging, world class fishing, hunting, hiking, horseback ... was founded several years ago to support U.S. Service ...
(Date:12/22/2014)... Pasadena sleep apnea dentist, ... apnea. Drowsy drivers are 15 times more likely to ... and some experts believe that sleep-deprived drivers may be ... Unfortunately, millions of Americans may be sleep-deprived without even ... Medicine, about 18 million Americans have sleep apnea, but ...
(Date:12/22/2014)... Texas (PRWEB) December 22, 2014 7,178 ... and bustle of Black Friday shopping and opted instead ... and marketing education company, for their 5th annual “Black ... charged just $7 to attend the 5 hour ... that they promptly donated to support two Central Texas ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once again ... provide logistics and support for one of Dallas’ largest holiday ... history of giving back to the community in which it ... Drive were Whataburger® and 99.5 The Wolf. , There is ... gifts to children who would otherwise not receive any is ...
Breaking Medicine News(10 mins):Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2
... discovered an accomplice in breast cancer a master control ... reactions orchestrated by a cancer-causing gene (or oncogene) named Wnt1. ... back-to-back papers featured on the cover of the August 15 ... about the regulation of a Wnt oncogene," explains lead author ...
... By Jenifer Goodwin HealthDay Reporter , ... mistakes, admitting the error, saying "I,m sorry" and offering ... lawsuits, new research shows. In 2001, University ... workers to report medical mistakes. The program included a ...
... Supports (CLASS) Act a largely overlooked component of the ... potential to transform long-term care financing in the United States ... latest issue of Public Policy & Aging Report ... The SCAN Foundation , this installment of PPAR ...
... This release is available in French . ... boys with low parental monitoring are more likely to befriend ... to a new study published in the journal Addictive ... de Montral and Sainte-Justine University Hospital Research Center found that ...
... fellow Amy Speed-Andrews has examined how a specialized Iyengar yoga ... who have completed treatment, makes a difference in their recovery. ... to fill out a questionnaire about their physical and mental ... yoga and again at the end. After analyzing the data ...
... are developing the first device able to transmit American ... just completing its initial field test by participants in ... "This is the first study of how deaf people ... project leader Eve Riskin, a UW professor of electrical ...
Cached Medicine News:Health News:Researchers identify breast cancer culprits 2Health News:When Doctors Admit Mistakes, Fewer Malpractice Suits Result, Study Says 2Health News:When Doctors Admit Mistakes, Fewer Malpractice Suits Result, Study Says 3Health News:CLASS Act analysis reveals America's long-term care future 2Health News:Heavy drug-use among bad boys curbed by parental monitoring and peers 2Health News:Deaf, hard-of-hearing students perform first test of sign language by cell phone 2Health News:Deaf, hard-of-hearing students perform first test of sign language by cell phone 3
... Delivery System (CDS) facilitates the ... the Aescula LV Left-Heart Lead. ... patented coronary sinus curve that ... access to the coronary sinus ...
... PCS2 system is Haemonetics ... collection of plasma and ... the collection of "jumbo" ... platelet-poor plasma with optional ...
Optipress II Automated Blood Component Extractor for the standardized separation of whole blood into high purity individual components...
... provides quick, convenient, repetitive dispensing for ... have a polyethylene plunger and a ... use with most reagents. Application: ... separate volumes can be selected for ...
Medicine Products: